Muscimol: GABA agonist therapy in schizophrenia

C. A. Tamminga, J. W. Crayton, T. N. Chase

Research output: Contribution to journalArticle

91 Scopus citations

Abstract

Muscimol (3-hydroxy-5-aminomethylisoxazole), originally isolated from 'Amanita muscaria', is the structural analogue of GABA. Muscimol was administered to six patients in a double-blind, placebo-controlled design. All subjects were diagnosed as having chronic schizophrenia. During high-dose muscimol treatment, all study subjects evidenced diffuse myoclonic twitching or somnolence, and many experienced vivid dreams, dizziness, and confusion. At dose levels below 5 mg, many patients experienced a tranquilizing effect from muscimol. These subjects, when receiving the active drug, reported feeling more relaxed and less anxious and claimed a positive drug experience, despite their lack of relief from psychotic thinking. No significant change in vital signs or routine laboratory studies occurred.

Original languageEnglish (US)
Pages (from-to)746-747
Number of pages2
JournalAmerican Journal of Psychiatry
Volume135
Issue number6
DOIs
StatePublished - Jan 1 1978

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Muscimol: GABA agonist therapy in schizophrenia'. Together they form a unique fingerprint.

  • Cite this